Glioblastma multiforme (GBM) is one of the most lethal primary brain tumors, with median survival of the patients, which is only slightly over one year. Researchers at Boston University School of Medicine (BUSM), in collaboration with researchers from the City of Hope, are looking toward novel therapeutic strategies for the treatment of GBM in the form of targeted therapies against a unique receptor, the interleukin-13 receptor (and) #945; chain variant 2 (IL13R (and) #945;2). ...Thursday, 2 October 2014
Researchers Find Promise in Treatments for Glioblastma Multiforme
Glioblastma multiforme (GBM) is one of the most lethal primary brain tumors, with median survival of the patients, which is only slightly over one year. Researchers at Boston University School of Medicine (BUSM), in collaboration with researchers from the City of Hope, are looking toward novel therapeutic strategies for the treatment of GBM in the form of targeted therapies against a unique receptor, the interleukin-13 receptor (and) #945; chain variant 2 (IL13R (and) #945;2). ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment